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Background: Oxidative stress and systemic inflammation is increased in end-stage renal 
disease (ESRD) patients. Due to the various effects of oxidative stress in ESRD patients, 
different antioxidants have been evaluated. 
Objectives: In this study, we evaluated the effect of oral N-acetylcysteine (NAC) as 
an antioxidant on the serum high-sensitive C-reactive protein (hs-CRP) and plasma 
hemoglobin levels in the ESRD patients who were under routine hemodialysis.
Patients and Methods: In this randomized placebo-controlled clinical trial, 51 ESRD patients 
under routine hemodialysis were randomly assigned to receive NAC 1200 mg daily for 1 
month (n=26) or placebo (n=25). Laboratory findings including hemoglobin, ferritin, hs-
CRP were measured in patients before and after treatment. 
Results: NAC group compared to placebo group had significantly higher ferritin levels 
before treatment (p=0.02) and lower phosphorus levels after treatment (p=0.03). 
Comparing the results before and after treatment in each group, a significant reduction 
in hematocrit (p=0.002), ferritin (p=0.006), hs-CRP (p=0.02) and an increase in alkaline 
phosphatase levels (p=0.005) in NAC group and significant reduction in calcium levels 
(p<0.001) in placebo group was detected. No major side effects were seen. 
Conclusions: One month treatment with oral NAC resulted in reduced levels of hematocrit, 
ferritin and Hs-CRP, indicative of role of NAC in controlling inflammation in ESRD 
patients under hemodialysis. However, NAC was not effective in treatment of anemia, 
although the treatment duration was low.
ABSTRACT
Implication for health policy/practice/research/medical education:
Oxidative stress and systemic inflammation is increased in end-stage renal disease patients.   Treatment with oral N-acetylcysteine 
1200 mg daily could reduce levels of  hematocrit, ferritin and Hs-CRP, indicative of  role of  N-acetylcysteine in controlling 
inflammation in end-stage renal disease patients under hemodialysis.
Please cite this paper as: Bashardoust B, Alaei R, Mohammadi Kebar S, Hasani S, Habibzadeh A.  The effect of  oral N-acetylcysteine 
on serum high sensitive CRP and plasma hemoglobin levels in end-stage renal disease patients under routine hemodialysis; a 
randomized placebo-controlled clinical trial. J Nephropathol. 2018;7(4):268-272. DOI: 10.15171/jnp.2018.53.
1. Background
End-stage renal disease (ESRD) patients represent a 
high cardiovascular risk population (1), where the extent 
of  cardiovascular risk is unexplained by traditional risk 
factors. ESRD and hemodialysis accompany with high 
oxidative stress and increased generation of  free oxidant 
radicals with impaired antioxidant neutralization. This 
yields to inflammation, endothelial dysfunction, anemia 
and accelerated atherosclerosis (1-3).
Previous studies have evaluated various antioxidants ef-
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fects in reducing oxidative stress in ESRD patients (1,4). 
Considering low cost, safety, with its beneficial effects, 
N-acetylcysteine (NAC) has been recommended as a 
potential anti-inflammatory and antioxidant drug in di-
alysis patients (5). NAC is a free radical scavenger that 
increases glutathione and inhibits inducible nitric oxide 
synthase, suppresses cytokine expression/release, and 
inhibits the expression of  adhesion molecules (6-8). It 
has been used extensively as a mucolytic agent, in the 
treatment of  acetaminophen toxicity, as a cytoprotective 
agent during cancer chemotherapy, and in the preven-
tion of  contrast-induced nephropathy (9,10). Also it is 
indicated that NAC acts as an adjuvant in the treatment 
of  chronic kidney disease (CKD) anemia (11).
2. Objectives
In this study, we aimed to evaluate the effects of  NAC 
as an antioxidant on inflammation by measuring high-
sensitive C-reactive protein (hs-CRP) and on anemia in 
hemodialysis patients.
3. Patients and Methods 
3.1. Patients
In this randomized placebo-controlled clinical trial, 51 
ESRD patients on regular hemodialysis 3 times weekly 
for at least 3 months in Bou-Ali dialysis center, Ardabil 
were recruited. Patients with vasculitis, cardiac disease, 
respiratory disorders, uncontrolled diabetes (HbA1C 
>7.5%) and those who receiving lipid-lowering agents 
and immunosuppressive drugs in the last 3 months were 
excluded from the study. Patients with primary hs-CRP 
below 6 mg/L, a history of  smoking, a known allergy 
to NAC, chronic inflammatory disease (e.g., rheumatic 
diseases), evidence of  malignancy, cardiac disease or he-
matologic diseases (e.g., leukemia or lymphoma), active 
infection, HIV or hepatitis B or C, abnormal liver func-
tion tests, use of  vitamin E or vitamin C or any anti-
oxidant, were excluded from the study too. Additionally, 
all study patients were strongly advised to not consume 
any nutritional material with known anti-oxidant effects. 
The trial is powered to detect an effect size of  d ≥0.70 
as statistically significant in a two-tailed test with α = 
0.05 and power of  0.80 with N = 25 per condition. As 
there was possibility that some patients do not complete 
the study, we included 30 patients in each group. Using 
RandList 1.2 software, random numbers were produced 
and according to sample size, patients were enrolled into 
the study. During the study period, four patients in NAC 
group (one with infection and three for personal issues) 
and five patients from placebo group (one died, two with 
infection and two for personal issues) were lost to fol-
low-up and were excluded (Figure 1). 
Figure 1. Flow diagram of  the study protocol.
3.2. Intervention and biochemical measurement
For a period of  month, patients received NAC 1200 mg 
daily (intervention group) or placebo (with the similar 
size, color and shape). Patients and the physician evaluat-
ing the treatment outcome were blinded to the regimens. 
To control the appropriate use of  medications, tablets 
were delivered to the patients weekly and participants 
gave back the used tablet sheets to be checked. Before 
and after intervention, blood samples were taken from 
each patient to measure complete blood cell count, fer-
ritin, hs-CRP, Ca, P and alkaline phosphatase (ALP). The 
blood samples for measuring all the above-mentioned 
variables were taken just before the initiation of  dialysis. 
3.3. Ethical considerations
The research followed the tenets of  the Declaration of 
Helsinki; the study protocol was approved by the eth-
ics committee of  the Ardabil University of  Medical Sci-
ences and all participants gave written informed consent 
before enrolling into the study. Besides that, the study 
proto col was registered in the Iranian Registry of  Clini-
cal Trials website (identifier: IRCT2016111030821N1; 
http://www.en.search.irct.ir/view/33908).
3.4. Statistical analysis
Results are expressed as mean ± standard deviation 
(SD) or percentage. The chi-squared and Fisher’s exact 
tests were used to compare categorical variables and the 
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Mann–Whitney U test and independent t test to compare 
continuous variables. Paired t test was used to compare 
post treatment results with baseline in each group; P val-
ues of  less than 0.05 were considered statistically signifi-
cant. All data were analyzed using SPSS 17 (version 17; 
SPSS Inc., Chicago, IL).
4. Results
Fifty-one patients were studied in NAC (n = 26) and pla-
cebo (n = 25) group. There was no significant difference 
between groups regarding baseline findings (Table 1). 
Laboratory findings before and after treatment in NAC 
and placebo group are shown in Table 2. Among vari-
ables, only ferritin levels before and phosphorus lev-
els after treatment were significantly different between 
groups. Comparing the results before and after treatment 
in each group, we observed significant changes in hema-
tocrit (P = 0.002), ferritin (P = 0.006), hs-CRP (P = 0.02) 
and ALP levels (P = 0.005) in NAC group and increase in 
calcium levels (P < 0.001) in placebo group. 
In order to better evaluate the efficacy of  treatment, we 
compared the percent of  changes in laboratory variables 
between groups and found only significant difference in 
calcium changes (Table 2). No major side-effects were 
reported following administration of  NAC.
5. Discussion
In this randomized clinical trial, we observed that oral 
NAC 1200 mg daily for one month can significantly im-
prove ferritin and hs-CRP levels. However, the percent-
age of  changes were not significantly different between 
NAC and placebo. 
Previous studies have indicated that oxidative stress may 
cause systemic inflammation and antioxidant neutraliza-
tion in hemodialysis patients (1-3). As an antioxidant, the 
effect of  NAC on oxidative stress has been evaluated in 
different studies (5,12-15). Swarnalatha et al (12) showed 
that NAC can decrease oxidative stress in hemodialy-
sis patients. Shahbazian et al (13) also reported, NAC 
administration would reduce oxidative stress in hemo-
dialysis patients. Giannikouris (14) explained that NAC 
Table 1. Baseline findings between NAC and placebo group
NAC group Placebo group P
Age (y) 65.50±11.05 62.76±14.47 0.45
Gender, No. (%) 0.88
Male 13 (50) 13 (52)
Female 13 (50) 12 (48)
Time on dialysis (mon) 41.09±16.15 38.29±14.80 0.052
Underlying cause, No. (%) 0.9
Hypertension 7 (26.9) 6 (24)
Diabetes mellitus 9 (34.6) 9 (36)
Glumerulonephritis 4 (15.4) 3 (12)
Unknown 6 (23.1) 7 (28)
Table 2. Laboratory findings before and after treatment in NAC and placebo group
NAC group Placebo group P value
Hemoglobin (g/dL) Before 12.34±1.47 11.89±1.71 0.31After 12.06±1.74 11.63±1.36 0.33
Hematocrit (%) Before 39.70±4.61 38.32±4.13 0.32After 37.94±5.27 37.04±4.04 0.49
Ferritin (ng/mL) Before 1317.04±675.08 867.04±743.03 0.021*After 1089.96±642.102 734.32±542.46 0.07
Platelets (×103/µL) Before 172.30±48.90 176.01±74.65 0.83After 166.81±69.98 185.56±72.64 0.35
hs-CRP (mg/L) Before 15.51±14.71 17.64±14.60 0.72After 9.60±2.10 13.57±2.31 0.22
ALP (IU/L) Before 510.57±301.23 457.36±220.67 0.47After 544.42±302.15 491.72±232.14 0.48
 P (mg/dL) Before 5.34±1.12 5.93±1.42 0.12After 5.09±1.23 5.90±1.45 0.03*
Ca (mg/dL) Before 9.54±0.82 9.75±1.12 0.45After 9.51±0.80 9.25±1.13 0.35
Hemoglobin change (%) -2.40±6.35 -1.44±9.54 0.67
Hematocrit change (%) -4.46±6.47 -2.59±9.81 0.42
Ferritin change (%) -16.60±23.32 5.30±71.95 0.14
Platelet change (%) -3.48±24.93 51.42±240.00 0.25
hs-CRP change (%) -10.33±108.32 18.24±139.98 0.41
ALP change (%) 9.20±2.73 8.77±21.12 0.93
P change (%) -3.2±16.83 2.26±28.36 0.40
Ca change (%) 0.19±1.77 -5.09±1.05 0.01*
Abbreviations: P, phosphorus; Ca, calcium; ALP, Alkaline phosphatase; hs-CRP, high-sensitive C-reactive protein.
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significantly decreased oxidative stress and inflammatory 
markers such as hs-CRP in dialysis patients. Purwanto 
and Prasetyo (15) also concluded that NAC administra-
tion for 8 weeks would result in reduction of  different 
inflammatory markers including hs-CRP in patients with 
continuous ambulatory peritoneal dialysis. 
NAC as a supplement therapy may be encouraging in 
ESRD patients, considering the role of  oxidative stress 
in anemia, inflammation and atherosclerosis in these pa-
tients (1). NAC supplementation shows the capability of 
inhibiting cytokines and pro-inflammatory biomarker 
such as hs-CRP. Giannikouris (14) suggested that treat-
ing hemodialysis patients with NAC could be associated 
with restoration of  important parameters of  antioxidant 
defense and reduction in the levels of  oxidative cellular 
damage mediators. This is probably due to the ability of 
NAC as an antioxidant to prevent the activation of  NF-
kB induction and inhibits induction of  expression and 
also secretion of  pro-inflammatory cytokines (16). Also, 
thiol in NAC inhibited the production pro-inflammation 
mediators and stimulated GSH cellular system (17). 
Oxidative stress on one hand and uremic toxins on the 
other hand could impair erythropoietin process in ESRD 
patients. It will increase the destruction of  erythrocytes 
membrane leading to anemia in ESRD patients (18). In 
this study we did not observe a significant change in 
hemoglobin levels following treatment with NAC. Nu-
merus studies recommended that NAC could improve 
anemia in hemodialysis patients. Swarnalatha et al (12) 
showed that NAC as an oral supplement may improve 
the treatment of  anemia. Giannikouris (14) also report-
ed higher hemoglobin levels compared to pre-treatment 
values. 
Inhibiting the inflammatory markers and oxidative stress 
will prevent erythrocytes destruction. In fact, NAC sup-
plementation may preserve membranous RBC reduc-
tases, prevent oxidative damage to the RBC membrane, 
prolong RBC survival, and improve uremic anemia (11). 
The difference between studies could be due to the dura-
tion of  treatment. We only treated patients for 1 month, 
but other studies duration were 2 to 3 months, while he-
moglobin levels depend on erythropoietic process which 
needs 120 days. 
Besides the efficacy of  any treatment, its safety is also 
an issue. Following treatment with NAC we observed no 
major side effects. Previous studies have also reported 
very few side effects (11). 
6. Conclusions
One month treatment with oral NAC resulted in reduced 
levels of  hematocrit, ferritin and hs-CRP, indicative of 
role of  NAC in controlling inflammation in ESRD pa-
tients under hemodialysis. However, NAC was not ef-
fective in treatment of  anemia, although the treatment 
duration was low.
Study limitations
 Our study is subject to limitations, such as the relatively 
small sample of  patients and short duration of  treat-
ment. Also, in this trial, we did not measure biomarkers 
of  oxidative stress.
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